Pfizer collaborates with BioNTech to develop coronavirus vaccine

By Nikita Chaurasia  | Date: 2020-03-17

Pfizer collaborates with BioNTech to develop coronavirus vaccine

Increasing numbers of coronavirus cases worldwide have prompted researchers to develop a potential vaccine candidate to treat COVID-19 patients. Pfizer Inc., one of the leading American pharmaceutical companies, has reportedly collaborated with BioNTech SE, an immunotherapy organization pioneering novel therapies for cancer and other serious diseases, to further this cause.

Sources cite that both the companies have agreed to a LOI (letter of intent) regarding the co-development and distribution of potential mRNA-based vaccines for the treatment of COVID-19. The companies have also inked material transfer and collaboration agreements to facilitating immediate working. 

Mikael Dolsten, President and Chief Scientific Officer, Worldwide Research, Development & Medical, Pfizer, said that the company’s successful and on-going relationship with BioNTech gives both the firms the resiliency to mobilize combined resources with exceptional speed in the face of this global challenge.

Integrating Pfizer’s regulatory, development and commercial capabilities with BioNTech’s mRNA vaccine technology and expertise would strengthen their company’s commitment to combatting this increasing pandemic as soon as possible.

Ugur Sahin, CEO and Co-Founder of BioNTech, said that this global pandemic demands for a worldwide effort. With this collaboration, BioNTech believes that it can fuel efforts to bring a COVID-19 vaccine for treating people across the globe.

Moreover, the two companies expects to leverage several research and development sites, including that in the U.S and Germany, to house the actions identified by the collaboration agreement.

Reliable reports claim that BioNTech and Pfizer are expected to team up quickly and finalize the conditions of the agreement such as financial terms, manufacturing, potential commercialization, and development activities over the next few weeks.

Meanwhile, on March 13, 2020, Pfizer declared a five-point plan calling on the biopharmaceutical companies to join the organization in committing to extraordinary collaboration to tackle COVID-19.

Source Credit - https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

L&T Technology Services partners with Qualcomm to amplify 5G adoption

L&T Technology Services partners with Qualcomm to amplify 5G adoption

By Nikita Chaurasia

L&T Technology Services Limited has recently announced that it is teaming up with Qualcomm Technologies, Inc., the world’s leading wireless technology innovator. With the latest collaboration, the firm plans to offer end-to-end solutions...

PNAS, Straive partner to deliver end-to-end content production services

PNAS, Straive partner to deliver end-to-end content production services

By Nikita Chaurasia

Renowned U.S.-based nonprofit and non-governmental organization, NAS (National Academy of Sciences), has reportedly collaborated with Straive, one of the leading technology-driven solutions providers for Content, EdTech, and Data. With this acquis...

Japan pushes innovations in 'deep tech' sector with solar cell technology

Japan pushes innovations in 'deep tech' sector with solar cell technology

By Nikita Chaurasia

Amid the most promising next-generation solar cell technology innovations, Enecoat Technologies, a provider of materials development services in Japan, is reportedly developing perovskite. Following its completion, the Kyoto-located start-up expec...

GIC to acquire majority shares in opulent Sani/Ikos properties

GIC to acquire majority shares in opulent Sani/Ikos properties

By Nikita Chaurasia

Singapore's sovereign wealth fund, GIC has agreed to pay around $2.2 billion to buy a majority stake in Sani/Ikos Group, a Mediterranean luxury resort operator, marking the largest transaction in the European resort market since the Covid-19 pand...

Excelra, Patcore partner to offer enhanced digital insights to customers

Excelra, Patcore partner to offer enhanced digital insights to customers

By Nikita Chaurasia

Excelra, a data and analytics solutions provider, has recently announced its partnership with Patcore, Inc., to provide better access to its analytics products and scientific data for customers in Japan. For the unversed, Excelra is one of the top...